QTTB | Q32 Bio Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	40.78 - 47.33
52 Week Range	8.24 - 47.33
Beta	-7.90
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	152,745
Average Volume	104,443
Shares Outstanding	12,059,800
Market Cap	516,400,636
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-03-28

Valuation
Profitability
Growth
Health
P/E Ratio	-9.52
Forward P/E Ratio	N/A
EPS	-4.50
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	39
Country

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

*Chart delayed

Analyzing fundamentals for QTTB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is very weak. For more detailed analysis please see QTTB Fundamentals page.

Watching at QTTB technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on QTTB Technicals page.